Read about Endologix
in the news

Embrace the evidence.

The Latest:

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

See Release

All News

Archives

Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session

Endologix’s DETOURTM System Earns Spot in Local and National Award Forums; Nominated for Prix Galien USA’s Best Medical Technology

Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a New Technology Add-on Payment for the DETOUR System

Endologix Announces that Lucas Buchanan Joins Board of Directors

Endologix Announces First Patients Treated with the DETOUR™ System, Advancing Treatment for Complex Peripheral Artery Disease